Format

Send to

Choose Destination
Cancer J. 2016 May-Jun;22(3):196-8. doi: 10.1097/PPO.0000000000000188.

Adjuvant Therapy Trials.

Author information

1
From the Gastrointestinal Oncology, University of California, San Francisco, CA.

Abstract

In 2015, ramucirumab and TAS-102 became the 10th and 11th drugs approved by the Food and Drug administration for the treatment of patients with colorectal cancer, not counting leucovorin, and yet only 3 agents, 5-fluorouracil, capecitabine, and oxaliplatin, have proven benefit in adjuvant treatment. In fact, there have been no additions (and 1 subtraction levamisole) to our arsenal of therapies for patients with stages II and III colon cancer for more than a decade. How did we get here? Are we stuck? And how do we move forward?

PMID:
27341598
PMCID:
PMC5349297
DOI:
10.1097/PPO.0000000000000188
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center